Skip to main navigation Skip to search Skip to main content

Personalized surveillance intervals for intraductal papillary mucinous neoplasm (IPMN): multicenter study using parametric models

  • Claudio Ricci*
  • , Stefano Crippa
  • , Johnathan Hee
  • , Hyesol Jung
  • , Gabriele Capurso
  • , Marco Ferronato
  • , José Lariño Noia
  • , Myrte Gorris
  • , Paula Ghaneh
  • , Ihsan Ekin Demir
  • , Nuzhat Ahmad
  • , Max Heckler
  • , Giulio Belfiori
  • , Francesca Aleotti
  • , Youngmin Han
  • , Wooil Kwon
  • , Gaetano Lauri
  • , Matteo Tacelli
  • , Olivier Busch
  • , Kulbir Mann
  • Marina Migliori, Paolo Giorgio Arcidiacono, Helmut Friess, Charles M. Vollmer, Thilo Hackert, Marc Besselink, Riccardo Casadei, Jin-Young Jang, Brian Kim-Poh Goh, Massimo Falconi, Giovanni Marchegiani
*Corresponding author for this work
  • University of Bologna
  • Interventional Pulmonology Unit, Policlinico S. Orsola
  • San Raffaele Scientific Institute
  • Singapore General Hospital
  • Ministry of Health, Government of Singapore
  • Seoul National University
  • University Hospital
  • University of Amsterdam
  • Amsterdam UMC
  • Liverpool University Hospitals NHS Foundation Trust
  • Technical University of Munich
  • University of Pennsylvania
  • Heidelberg University 
  • University of Hamburg
  • Duke-NUS Medical School
  • University of Padua

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)

Abstract

Objective: The aim was to build a calculator for personalized surveillance of BD-IPMNs. Summary background Data: The interval time for surveillance of low-risk branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) has not been established yet. Methods: The study included an international cohort of BD-IPMNs without worrisome features (WFs) or high-risk stigmata (HRS). IPMN evolution was defined as the occurrence of HRS or WFs. The derivation cohort comprised 60% of patients. The validation group comprised the remaining patients. A parametric survival model was developed in the derivation cohort using Akaike (AIC) and Bayesian (BIC) information criteria and c-index. A “k-fold” validation was used to measure the covariate effect on the accelerated failure time. Two models (“standard” and “conservative”) were built and validated using the second cohort. Results: The derivation and validation cohorts included 1,992 and 1,119 BD-IPMNs. The lognormal distribution best fitted the derivation cohort (AIC=2673; BIC=2718). The pooled c-index was 0.689 (0.668 to 0.718, 95%CI). The factors reducing the time needed for IPMN evolution were age [- 2% (-1% to -3%) for each year] and cyst size [-2% (0% to -3%); for each mm]. The “conservative” model, called PANORAMA, was the only one that correctly classified the validation cohort (c-index 0.712 vs 0.696; P=0.072). Conclusion and Relevance: The development of WF and HRS is influenced by the patient’s age and cyst size. After a prudential first control at six months, repeating a semestral/annual follow-up in this time frame could be too tight.
Original languageEnglish
JournalAnnals of surgery
Early online date2025
DOIs
Publication statusE-pub ahead of print - 2025

Keywords

  • branch-duct intraductal papillary mucinous neoplasm

Fingerprint

Dive into the research topics of 'Personalized surveillance intervals for intraductal papillary mucinous neoplasm (IPMN): multicenter study using parametric models'. Together they form a unique fingerprint.

Cite this